Intellectual Property

The Cyprus IP Box Regime

The Cyprus IP Box is one of the most competitive intellectual-property tax regimes in the EU. It allows a Cyprus tax-resident company to treat 80% of the net qualifying profit from qualifying IP as a deemed deductible expense, so that only the remaining 20% is taxed at the standard corporate rate. With the corporate tax rate at 15% from 1 January 2026, that produces an effective rate of roughly 3% on qualifying IP income (it was around 2.5% under the previous 12.5% rate). We advise on whether your IP and income qualify, and on how to structure ownership and R&D to claim the benefit on a sound footing.

The regime is set out in the Income Tax Law, N.118(I)/2002 (as amended), and was rewritten with effect from 1 July 2016 to comply with the OECD’s modified “nexus” approach under BEPS Action 5. It has been reviewed and accepted as compliant by the OECD and the EU Code of Conduct Group, which is what gives it long-term credibility, unlike older “grandfathered” regimes elsewhere.

How the relief works

Of the net profit from a qualifying IP asset, 80% is deducted for tax purposes and only 20% remains taxable:

20% taxable × 15% corporate tax ≈ 3% effective rate (where the nexus fraction is 100%).

The relief applies to the qualifying IP income, which can include:

• royalties and licence fees for the use of the qualifying IP;
• the embedded IP element of income from selling products or services that use the qualifying IP;
• gains on the disposal of qualifying IP (subject to the capital-vs-revenue distinction — see below); and
• compensation or damages received for infringement of the qualifying IP.

What IP qualifies

Qualifying assets are those that involve genuine research and development, namely:

• patents (granted by any patent office);
• copyrighted software (registration is not required — copyright arises on creation);
• utility models;
• plant breeders’ rights;
• orphan drug designations; and
• supplementary protection certificates for patented pharmaceutical and plant-protection products.

Importantly, trademarks, brand names, image rights and other marketing-related IP do not qualify — this exclusion is required by the OECD nexus rules.

The nexus approach — why how you developed the IP matters

The benefit is not automatic on the income; it is linked to how much of the R&D you actually did. The exempt portion is calculated using the nexus fraction:

(Qualifying expenditure ÷ Overall expenditure) × Qualifying IP profit × 80%

• Qualifying expenditure = R&D you incurred directly, plus R&D outsourced to unrelated parties. It can be uplifted by up to 30% (capped at overall expenditure).
• Overall expenditure = qualifying expenditure, plus R&D outsourced to related parties, plus the cost of acquiring the IP.

The effect is that a company developing its own IP in-house gets close to the full benefit, while a company that simply buys finished IP, or outsources heavily to group companies, gets a diluted benefit and a higher effective rate. Substance matters: genuine R&D activity, and Cyprus-based decision-making, underpin the claim.

Worked example

A Cyprus company licenses patented technology it developed itself and earns €500,000 of net qualifying profit. Because the R&D was carried out in-house, the nexus fraction is effectively 100%:

• 80% deduction = €400,000 exempt;
• taxable income = €100,000;
• tax at 15% = €15,000 — an effective rate of 3%.

If part of that R&D had been outsourced to group companies, or the IP had been acquired rather than developed, the nexus fraction would fall below 100% and the effective rate would rise correspondingly. We model your specific R&D profile before you rely on the headline rate.

Beyond the headline rate

The IP Box sits alongside other features of the Cyprus system:

• Capital-nature disposals of qualifying IP may fall outside taxation altogether, rather than simply benefiting from the 80% deduction. The capital-vs-revenue characterisation matters and should be assessed case by case.
• Amortisation / capital allowances — the cost of acquiring qualifying IP can generally be written off over its useful life (up to 20 years), deductible against taxable income.
• No amortisation clawback of the kind found in some other EU regimes.
• Combination with other incentives — the regime can be combined with the Notional Interest Deduction and Cyprus’s double-tax-treaty network for efficient overall structuring.

Compliance and documentation

The benefit has to be supported. Companies claiming it should keep, on an asset-by-asset basis: identification of each qualifying asset; tracking of qualifying and overall expenditure; the nexus calculation and the resulting exempt-income computation; documentation characterising the IP income; and transfer-pricing documentation for any related-party R&D or IP transactions. The Cyprus Tax Department can request this on audit, and inadequate records can mean the benefit is disallowed.

Who it suits

The IP Box is especially valuable for software and SaaS businesses, technology and R&D-intensive companies, pharmaceutical and life-sciences businesses (patents, SPCs, orphan-drug designations), and manufacturers with patented processes or technology.

How we help

• assessing whether your assets and income qualify;
• structuring IP ownership and R&D so the nexus fraction — and the benefit — is as strong as the facts allow;
• preparing the licensing, assignment and R&D agreements that underpin the structure;
• securing the underlying rights — see Intellectual Property;
• putting in place the substance and ongoing compliance the regime expects;
• working alongside your tax advisors on the nexus computation and the annual claim.

Frequently asked questions

What is the effective tax rate? Approximately 3% on qualifying IP income, where the nexus fraction is 100%: 20% of the profit remains taxable after the 80% deduction, taxed at the 15% corporate rate. The rate rises where the nexus fraction is below 100%.

Do trademarks qualify? No. Trademarks, brands and marketing-related IP are excluded under the OECD nexus rules. Patents and copyrighted software are the most common qualifying assets.

Can software companies use it? Yes — copyrighted software is a core qualifying asset, and copyright arises automatically on creation, so formal registration is not required.

What if we acquired the IP instead of developing it? Acquired IP can still qualify, but the acquisition cost sits in the “overall expenditure” denominator of the nexus fraction, which dilutes the benefit. Carrying out further qualifying R&D in Cyprus on the acquired IP improves the position.

Is the regime EU/OECD compliant? Yes. The 2016 rewrite aligned it with OECD BEPS Action 5 and the EU Code of Conduct criteria, and it has been reviewed as compliant.

Can it be combined with other incentives? Yes — commonly with the Notional Interest Deduction and the double-tax-treaty network.

The content of this page is provided for general information purposes only and does not constitute legal, tax or other professional advice. It should not be relied upon as a substitute for advice tailored to your specific circumstances. The Cyprus IP Box regime is tax-led; eligibility, the nexus calculation and any effective tax rate depend on your individual facts and must be confirmed with a qualified Cyprus tax advisor. Laws, regulations, rates and procedures change and may have changed since this page was last updated. No lawyer  – client relationship is created by accessing or reading this page. You should obtain specific professional advice before taking, or refraining from, any action on the basis of this content. Theodorou Law Firm accepts no liability for any loss arising from reliance on the information provided here.